visual interface to drug design application v4.0.3 (OpenEye Scientific Software Inc)
90
Structured Review
OpenEye Scientific Software Inc
visual interface to drug design application v4.0.3
Visual Interface To Drug Design Application V4.0.3, supplied by OpenEye Scientific Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/visual+interface+to+drug+design+application+v4%2E0%2E3/visual+interface+to+drug+design+application+v4+0+3/pm26408454-165-3-21
Average 90 stars, based on 1 article reviews
Visual Interface To Drug Design Application V4.0.3, supplied by OpenEye Scientific Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/visual+interface+to+drug+design+application+v4%2E0%2E3/visual+interface+to+drug+design+application+v4+0+3/pm26408454-165-3-21
Average 90 stars, based on 1 article reviews
visual interface to drug design application v4.0.3 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis. Article Snippet: Deregulation of protein synthesis is a common event in cancer.. As MAPK-interacting kinases (Mnks) play critical roles in regulation of protein synthesis, they have emerged as novel anti-cancer targets.. Mnks phosphorylate eukaryotic initiation factor 4E (eIF4E) and promote eIF4E-mediated oncogenic activity. |